Table 4 Univariate analysis of disease-free survival among patients
Variable | Category | N(%) | OS (Median(IQR)) | Survival rate(%) | P |
|---|---|---|---|---|---|
Age y | <49 | 141 (46.38) | 52 [16,87] | 57.45 | 0.0194a |
> = 49 | 163 (53.62) | 31 [12,65] | 47.85 | ||
Menopausal status | Pre | 161 (52.96) | 50 [17,87] | 57.14 | 0.0052a |
Post | 143 (47.04) | 26 [11,64] | 46.85 | ||
Gravidity | 0 | 35 (11.51) | 44 [16,90] | 51.43 | 0.6329 |
> = 1 | 269 (88.49) | 39 [12,75] | 52.79 | ||
Parity | 0 | 51 (16.78) | 51 [15,86] | 52.94 | 0.5262 |
> = 1 | 253 (83.22) | 38 [12,75] | 52.57 | ||
Stage | Early | 185 (60.86) | 59 [36,88] | 74.59 | <.0001a |
Late | 119 (39.14) | 14 [8,28] | 18.49 | ||
FIGO Stage | I | 141 (46.38) | 62 [44,90] | 81.56 | <.0001a |
II | 44 (14.47) | 42 [17.5,80] | 50 | ||
III | 104 (34.21) | 15 [9,30.5] | 20.19 | ||
IV | 15 (4.93) | 9 [0.5,22] | 6.67 | ||
Histotype | Clear cell | 118 (38.82) | 52.5 [14,85] | 61.86 | 0.0091a |
Endometrioid | 186 (61.18) | 34.5 [12,70] | 46.24 | ||
Lymphadenectomy | Yes | 51 (16.77) | 12 [6,26] | 23.53 | <.0001a |
No | 253 (83.22) | 48 [17,82] | 58.1 | ||
Metastasis of LN | Positive | 213 (70.07) | 54 [24,86] | 64.79 | <.0001a |
Negative | 40 (13.16) | 13 [7,31] | 22.5 | ||
Residual disease | >1 cm | 231 (75.99) | 53 [22,84] | 17.81 | <.0001a |
None or <1 cm | 73 (24.01) | 12 [5,23] | 63.2 | ||
CA125 normal | Yes | 55 (18.09) | 64 [48,97] | 74.55 | <.0001a |
No | 249 (81.91) | 30 [12,70] | 47.39 | ||
Tumor size(cm) | <10 | 153 (50.33) | 40 [13,77] | 50.33 | 0.7834 |
≥10 | 151 (49.67) | 38 [13,75] | 54.3 | ||
Tumor side | Unilateral | 212 (69.74) | 50.5 [14.5,83] | 60.85 | <.0001a |
Bilateral | 92 (30.26) | 27.5 [12,55.5] | 33.7 | ||
Endometriosis | No | 235 (77.30) | 31 [12,69] | 44.68 | <.0001a |
Yes | 69 (22.70) | 60 [36,89] | 78.26 | ||
Endometrial disorders | No | 252 (82.89) | 38 [13,75.5] | 51.19 | 0.3357 |
Yes | 52 (17.11) | 48 [13,76] | 57.69 | ||
Endometrial cancer | No | 252 (82.89) | 38 [13,75.5] | 51.19 | 0.2503 |
Yes | 27 (8.88) | 49 [18,86] | 59.26 | ||
Hypertension | No | 250 (82.24) | 41 [14,76] | 52.8 | 0.4164 |
Yes | 54 (17.763) | 29.5 [11,68] | 50 | ||
Chemotherapy cycle | <4 | 191 (62.83) | 51 [19,83] | 61.78 | <.0001a |
≥4 | 100 (32.89) | 19 [11,45] | 32 | ||
Chemotherapy resistence | No | 252 (82.89) | 51.5 [24,84] | 63.1 | <.0001a |
Yes | 52 (17.11) | 7.5[3,10] | 0 |